Is it the drug or the weight loss causing it
Ludvik B, Giorgino F, Jdar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Those who took tirzepatide lost a greater percentage of body weight each month, compared to semaglutide: an average of 5.9% of their body weight after 3 months
Brain complexity, environmental factors, and individual differences in addiction biology mean that mechanisms are still theoretical until confirmed in robust clinical research
HanAll's second FcRn inhibitor HL161ANS to be added to the development program of its licensed partner [press release]
doi: 10.1093/nar/gky1000 45 KaderA